BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 7506280)

  • 1. Long-term persistence of zidovudine resistance mutations in plasma isolates of human immunodeficiency virus type 1 of dideoxyinosine-treated patients removed from zidovudine therapy.
    Smith MS; Koerber KL; Pagano JS
    J Infect Dis; 1994 Jan; 169(1):184-8. PubMed ID: 7506280
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term persistence of AZT-resistance mutations in the plasma HIV-1 of patients removed from AZT therapy.
    Smith MS; Koerber KL; Pagano JS
    Leukemia; 1994 Apr; 8 Suppl 1():S179-82. PubMed ID: 8152287
    [TBL] [Abstract][Full Text] [Related]  

  • 3. pol mutations conferring zidovudine and didanosine resistance with different effects in vitro yield multiply resistant human immunodeficiency virus type 1 isolates in vivo.
    Eron JJ; Chow YK; Caliendo AM; Videler J; Devore KM; Cooley TP; Liebman HA; Kaplan JC; Hirsch MS; D'Aquila RT
    Antimicrob Agents Chemother; 1993 Jul; 37(7):1480-7. PubMed ID: 7689822
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel mutation in the human immunodeficiency virus type 1 reverse transcriptase gene that encodes cross-resistance to 2',3'-dideoxyinosine and 2',3'-dideoxycytidine.
    Gu Z; Gao Q; Li X; Parniak MA; Wainberg MA
    J Virol; 1992 Dec; 66(12):7128-35. PubMed ID: 1279198
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of evolutionary limitations of HIV-1 multidrug resistance to optimize therapy.
    Chow YK; Hirsch MS; Merrill DP; Bechtel LJ; Eron JJ; Kaplan JC; D'Aquila RT
    Nature; 1993 Feb; 361(6413):650-4. PubMed ID: 7679778
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Zidovudine-resistant human immunodeficiency virus type 1 genomes detected in plasma distinct from viral genomes in peripheral blood mononuclear cells.
    Smith MS; Koerber KL; Pagano JS
    J Infect Dis; 1993 Feb; 167(2):445-8. PubMed ID: 7678429
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase.
    St Clair MH; Martin JL; Tudor-Williams G; Bach MC; Vavro CL; King DM; Kellam P; Kemp SD; Larder BA
    Science; 1991 Sep; 253(5027):1557-9. PubMed ID: 1716788
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genotypic evolution of HIV-1 isolates from patients after a switch of therapy from zidovudine to didanosine.
    Masquelier B; Pellegrin I; Ruffault A; Ragnaud JM; Morlat P; Michelet C; Doignon F; Biteau N; Fleury HJ
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Apr; 8(4):330-4. PubMed ID: 7533640
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human immunodeficiency virus type 1 drug susceptibility during zidovudine (AZT) monotherapy compared with AZT plus 2',3'-dideoxyinosine or AZT plus 2',3'-dideoxycytidine combination therapy. The protocol 34,225-02 Collaborative Group.
    Larder BA; Kohli A; Bloor S; Kemp SD; Harrigan PR; Schooley RT; Lange JM; Pennington KN; St Clair MH
    J Virol; 1996 Sep; 70(9):5922-9. PubMed ID: 8709213
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detection of mutations associated with zidovudine resistance in human immunodeficiency virus by use of the polymerase chain reaction.
    Richman DD; Guatelli JC; Grimes J; Tsiatis A; Gingeras T
    J Infect Dis; 1991 Dec; 164(6):1075-81. PubMed ID: 1720152
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro selection of variants of human immunodeficiency virus type 1 resistant to 3'-azido-3'-deoxythymidine and 2',3'-dideoxyinosine.
    Gao Q; Gu ZX; Parniak MA; Li XG; Wainberg MA
    J Virol; 1992 Jan; 66(1):12-9. PubMed ID: 1727474
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug resistance and heterogeneous long-term virologic responses of human immunodeficiency virus type 1-infected subjects to zidovudine and didanosine combination therapy. The AIDS Clinical Trials Group 143 Virology Team.
    Shafer RW; Iversen AK; Winters MA; Aguiniga E; Katzenstein DA; Merigan TC
    J Infect Dis; 1995 Jul; 172(1):70-8. PubMed ID: 7541064
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Persistence of azidothymidine-resistant human immunodeficiency virus type 1 RNA genotypes in posttreatment sera.
    Albert J; Wahlberg J; Lundeberg J; Cox S; Sandström E; Wahren B; Uhlén M
    J Virol; 1992 Sep; 66(9):5627-30. PubMed ID: 1380098
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reverse transcriptase mutations in sequential HIV-1 isolates in a patient with AIDS.
    Gurusinghe AD; Land SA; Birch C; McGavin C; Hooker DJ; Tachedjian G; Doherty R; Deacon NJ
    J Med Virol; 1995 Jul; 46(3):238-43. PubMed ID: 7561796
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-level resistance to zidovudine but not to zalcitabine or didanosine in human immunodeficiency virus from children receiving antiretroviral therapy.
    Husson RN; Shirasaka T; Butler KM; Pizzo PA; Mitsuya H
    J Pediatr; 1993 Jul; 123(1):9-16. PubMed ID: 8391570
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of zidovudine resistance mutations in patients receiving prolonged didanosine monotherapy.
    Demeter LM; Nawaz T; Morse G; Dolin R; Dexter A; Gerondelis P; Reichman RC
    J Infect Dis; 1995 Dec; 172(6):1480-5. PubMed ID: 7594706
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3'-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase.
    Tisdale M; Kemp SD; Parry NR; Larder BA
    Proc Natl Acad Sci U S A; 1993 Jun; 90(12):5653-6. PubMed ID: 7685907
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT).
    Larder BA; Kemp SD
    Science; 1989 Dec; 246(4934):1155-8. PubMed ID: 2479983
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sequence analysis of reverse transcriptase genes of zidovudine (AZT)-resistant and -sensitive human immunodeficiency virus type 1 strains.
    Sheehy N; Desselberger U
    J Gen Virol; 1993 Feb; 74 ( Pt 2)():223-8. PubMed ID: 7679140
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Two-drug combinations of zidovudine, didanosine, and recombinant interferon-alpha A inhibit replication of zidovudine-resistant human immunodeficiency virus type 1 synergistically in vitro.
    Johnson VA; Merrill DP; Videler JA; Chou TC; Byington RE; Eron JJ; D'Aquila RT; Hirsch MS
    J Infect Dis; 1991 Oct; 164(4):646-55. PubMed ID: 1716649
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.